Literature DB >> 12831411

Plasma volume expansion by medium molecular weight hydroxyethyl starch in neonates: a pilot study.

Jean-Michel Liet1, Anne-Sophie Bellouin, Cécile Boscher, Corinne Lejus, Jean-Christophe Rozé.   

Abstract

OBJECTIVE: To study the renal effects (measured by creatininemia) of plasma volume expansion with a medium molecular weight hydroxyethyl starch in the newborn.
DESIGN: A prospective, randomized, double-blinded, pilot study. PATIENTS: The study included 26 neonates weighing 690-4030 g (gestational age, 26-40 wks), without cardiac or renal failure or major hemostasis abnormalities and requiring a peripherally inserted central catheter for parenteral nutrition.
SETTING: Pediatric and neonatal intensive care unit of a university-affiliated hospital.
INTERVENTIONS: Plasma volume expansion was performed to facilitate insertion of the central catheter. After parental consent, neonates were randomly allocated to receive intravenous infusions at 10 mL.kg(-1) of 5% albumin or 6% hydroxyethyl starch 200/0.5. Sample size was calculated to detect an increase in mean creatininemia of >20 micromol.L(-1) (with alpha = 0.05, beta = 0.80).
MEASUREMENTS AND MAIN RESULTS: No clinically or statistically significant differences were found between the two groups 6 hrs, 24 hrs, 48 hrs, and 7 days after plasma volume expansion. The study could detect an increase in creatininemia > or =20 micromol.L(-1) with a power of 80%.
CONCLUSIONS: In 13 healthy neonates, plasma volume expansion with 10 mL.kg(-1) of 6% hydroxyethyl starch 200/0.5 does not increase creatininemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12831411     DOI: 10.1097/01.PCC.0000074262.84240.1E

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  4 in total

Review 1.  Early volume expansion for prevention of morbidity and mortality in very preterm infants.

Authors:  D A Osborn; N Evans
Journal:  Cochrane Database Syst Rev       Date:  2004

2.  Effects of a predominantly hydroxyethyl starch (HES)-based and a predominantly non HES-based fluid therapy on renal function in surgical ICU patients.

Authors:  Franziska Schabinski; Janaina Oishi; Fabio Tuche; Alain Luy; Yasser Sakr; Donald Bredle; Christiane Hartog; Konrad Reinhart
Journal:  Intensive Care Med       Date:  2009-06-17       Impact factor: 17.440

Review 3.  Safety evaluation on low-molecular-weight hydroxyethyl starch for volume expansion therapy in pediatric patients: a meta-analysis of randomized controlled trials.

Authors:  Lixia Li; Yongyang Li; Xiaoxing Xu; Bo Xu; Rongrong Ren; Yan Liu; Jian Zhang; Bin He
Journal:  Crit Care       Date:  2015-03-10       Impact factor: 9.097

Review 4.  [Hydroxyethylstarch (HES)].

Authors:  Joachim Boldt
Journal:  Wien Klin Wochenschr       Date:  2004-03-31       Impact factor: 2.275

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.